BioMarin Pharmaceutical Inc.
BMRN
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPSā¦ read more
Healthcare
Biotechnology
27 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$64.41
Price-0.34%
-$0.22
1Y
Price
Market Cap
$12.449b
Large
Price/Earnings 3y Avg5y Avg
31x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+22.5%
EBITDA Margin+4.5%
Net Profit Margin+14.1%
Free Cash Flow Margin+22.5%
EBITDA Margin+4.5%
Net Profit Margin+14.1%
Free Cash Flow MarginRevenue
$3.407b
+5.8%
1y CAGR+12.2%
3y CAGR+13.0%
5y CAGREarnings
$72.972m
-79.1%
1y CAGR+19.1%
3y CAGR+18.9%
5y CAGREPS
$0.39
-78.3%
1y CAGR+18.1%
3y CAGR+17.9%
5y CAGRBook Value
$6.322b
$11.723b
Assets$5.402b
Liabilities$4.202b
DebtDebt to Assets
35.8%
10.9x
Debt to EBITDAFree Cash Flow
$732.878m
+1.1%
1y CAGR+291.4%
3y CAGR+217.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company